サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1157567

髄膜炎菌ワクチンの世界市場：2030年までの予測

Meningococcal Vaccines market research report - Forecast till 2030
出版日: | 発行: Market Research Future | ページ情報: 英文 120 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
髄膜炎菌ワクチンの世界市場：2030年までの予測
出版日: 2022年09月19日
発行: Market Research Future
ページ情報: 英文 120 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の髄膜炎菌ワクチンの市場規模は、レビュー期間中に7.29%のCAGRで推移し、2030年末までに59億1000万米ドルに達すると予測されます。市場を牽引する主な要因は、予防接種への関心の高まりや、抗体イノベーションのための研究開発の拡大です。また、予防接種プロジェクトは、市場発展を後押しすると考えられています。ただし、厳格な行政規則と審査が市場発展の妨げになると予想されます。

当レポートでは、世界の髄膜炎菌ワクチン市場について調査し、市場規模や予測、市場力学、セグメント別の市場分析、競合情勢、主要企業のプロファイルなどの情報を提供しています。

目次

第1章 エグゼクティブサマリー

第2章 市場イントロダクション

  • 定義
  • 調査範囲
  • 調査目的
  • 市場構造
  • 前提条件と制限

第3章 調査手法

  • データマイニング
  • 2次調査
  • 1次調査
  • 一次回答者の内訳
  • 予測テクニック
  • 市場規模推計の調査方法
  • データの三角測量
  • 検証

第4章 市場力学

  • 概要
  • 促進要因
    • トラベルワクチンの認知度と急増
    • ワクチン技術の研究開発の増加
  • 抑制要因
    • 厳格な規制ガイドラインと製品リコール
  • 機会
    • 国家予防接種プログラムへの参加の増加

第5章 市場要因分析

  • バリューチェーン分析
    • 研究開発
    • 製造
    • 流通・販売
    • 販売後のモニタリング
  • ポーターのファイブフォースモデル
  • COVID-19が世界の髄膜炎菌ワクチン市場に与える影響
    • 概要
    • サプライチェーンへの影響
    • 髄膜炎菌ワクチンの生産への影響
    • 主要企業への影響

第6章 世界の髄膜炎菌ワクチン市場：ワクチンタイプ別

  • 概要
  • 結合型
  • 被膜下
  • 多糖体

第7章 世界の髄膜炎菌ワクチン市場：血清型別

  • 概要
  • MENACWY
  • MENB/BC
  • MENC
  • MENAC
  • MENA

第8章 世界の髄膜炎菌ワクチン市場：エンドユーザー別

  • 概要
  • 病院
  • 研究機関および学術機関
  • その他

第9章 世界の髄膜炎菌ワクチン市場：地域別

  • 概要
  • 北米
    • 米国
    • カナダ
  • 欧州
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • スペイン
    • その他欧州
  • アジア太平洋
    • 日本
    • 中国
    • インド
    • オーストラリア
    • 韓国
    • その他アジア太平洋
  • その他の地域
    • 中東
    • アフリカ
    • ラテンアメリカ

第10章 競合情勢

  • 概要
  • 競合ベンチマーキング
  • 世界の髄膜炎菌ワクチン市場における主な成長戦略
  • 世界の髄膜炎菌ワクチン市場における開発数での主要企業
  • 主な開発分析
  • 主な主な発展と成長戦略
    • 製品の発売/製品の承認
    • パートナーシップ/契約
  • 財務マトリックス
    • 販売（2021年、金額）
    • 研究開発費（2021年、金額）

第11章 企業プロファイル

  • PFIZER INC.
  • NOVARTIS AG
  • SANOFI S.A.
  • SERUM INSTITUTE OF INDIA PVT. LTD.
  • GLAXOSMITHKLINE PLC.
  • MERCK & CO., INC.
  • INCEPTA PHARMACEUTICALS LTD.
  • BIO-MED
  • WALVAX BIOTECHNOLOGY CO., LTD.
  • BIO-MANGUINHOS

第12章 付録

  • 参考文献
  • 関連レポート
図表

LIST OF TABLES

  • TABLE 1 LIST OF ASSUMPTIONS & LIMITATIONS
  • TABLE 2 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS
  • TABLE 3 GLOBAL: MENINGOCOCCAL VACCINES MARKET, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 4 GLOBAL: MENINGOCOCCAL VACCINES MARKET, FOR CONJUGATE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5 GLOBAL: MENINGOCOCCAL VACCINES MARKET, FOR SUBCAPSULAR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 6 GLOBAL: MENINGOCOCCAL VACCINES MARKET, FOR POLYSACCHARIDE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7 GLOBAL: MENINGOCOCCAL VACCINES MARKET, BY SEROTYPE, 2018-2030 (USD MILLION)
  • TABLE 8 GLOBAL: MENINGOCOCCAL VACCINES MARKET FOR MENACWY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9 GLOBAL: MENINGOCOCCAL VACCINES MARKET, FOR MENB/BC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10 GLOBAL: MENINGOCOCCAL VACCINES MARKET, FOR MENC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11 GLOBAL: MENINGOCOCCAL VACCINES MARKET, FOR MENAC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12 GLOBAL: MENINGOCOCCAL VACCINES MARKET, FOR MENA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13 GLOBAL: MENINGOCOCCAL VACCINES MARKET, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 14 GLOBAL: MENINGOCOCCAL VACCINES MARKET FOR HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15 GLOBAL: MENINGOCOCCAL VACCINES MARKET, FOR RESEARCH & ACADEMIC INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16 GLOBAL: MENINGOCOCCAL VACCINES MARKET, FOR OTHERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17 GLOBAL: MENINGOCOCCAL VACCINES MARKET, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18 NORTH AMERICA: MENINGOCOCCAL VACCINES MARKET, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 19 NORTH AMERICA: MENINGOCOCCAL VACCINES MARKET, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 20 NORTH AMERICA: MENINGOCOCCAL VACCINES MARKET, BY SEROTYPE, 2018-2030 (USD MILLION)
  • TABLE 21 NORTH AMERICA: MENINGOCOCCAL VACCINES MARKET, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 22 US: MENINGOCOCCAL VACCINES MARKET, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 23 US: MENINGOCOCCAL VACCINES MARKET, BY SEROTYPE, 2018-2030 (USD MILLION)
  • TABLE 24 US: MENINGOCOCCAL VACCINES MARKET, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 25 CANADA: MENINGOCOCCAL VACCINES MARKET, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 26 CANADA: MENINGOCOCCAL VACCINES MARKET, BY SEROTYPE, 2018-2030 (USD MILLION)
  • TABLE 27 CANADA: MENINGOCOCCAL VACCINES MARKET, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 28 EUROPE: MENINGOCOCCAL VACCINES MARKET, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 29 EUROPE: MENINGOCOCCAL VACCINES MARKET, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 30 EUROPE: MENINGOCOCCAL VACCINES MARKET, BY SEROTYPE, 2018-2030 (USD MILLION)
  • TABLE 31 EUROPE: MENINGOCOCCAL VACCINES MARKET, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 32 GERMANY: MENINGOCOCCAL VACCINES MARKET, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 33 GERMANY: MENINGOCOCCAL VACCINES MARKET, BY SEROTYPE, 2018-2030 (USD MILLION)
  • TABLE 34 GERMANY: MENINGOCOCCAL VACCINES MARKET, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 35 FRANCE: MENINGOCOCCAL VACCINES MARKET, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 36 FRANCE: MENINGOCOCCAL VACCINES MARKET, BY SEROTYPE, 2018-2030 (USD MILLION)
  • TABLE 37 FRANCE: MENINGOCOCCAL VACCINES MARKET, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 38 UK: MENINGOCOCCAL VACCINES MARKET, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 39 UK: MENINGOCOCCAL VACCINES MARKET, BY SEROTYPE, 2018-2030 (USD MILLION)
  • TABLE 40 UK: MENINGOCOCCAL VACCINES MARKET, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 41 ITALY: MENINGOCOCCAL VACCINES MARKET, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 42 ITALY: MENINGOCOCCAL VACCINES MARKET, BY SEROTYPE, 2018-2030 (USD MILLION)
  • TABLE 43 ITALY: MENINGOCOCCAL VACCINES MARKET, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 44 SPAIN: MENINGOCOCCAL VACCINES MARKET, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 45 SPAIN: MENINGOCOCCAL VACCINES MARKET, BY SEROTYPE, 2018-2030 (USD MILLION)
  • TABLE 46 SPAIN: MENINGOCOCCAL VACCINES MARKET, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 47 REST OF EUROPE: MENINGOCOCCAL VACCINES MARKET, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 48 REST OF EUROPE: MENINGOCOCCAL VACCINES MARKET, BY SEROTYPE, 2018-2030 (USD MILLION)
  • TABLE 49 REST OF EUROPE: MENINGOCOCCAL VACCINES MARKET, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 50 ASIA-PACIFIC: MENINGOCOCCAL VACCINES MARKET, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 51 ASIA-PACIFIC: MENINGOCOCCAL VACCINES MARKET, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 52 ASIA-PACIFIC: MENINGOCOCCAL VACCINES MARKET, BY SEROTYPE, 2018-2030 (USD MILLION)
  • TABLE 53 ASIA-PACIFIC: MENINGOCOCCAL VACCINES MARKET, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 54 JAPAN: MENINGOCOCCAL VACCINES MARKET, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 55 JAPAN: MENINGOCOCCAL VACCINES MARKET, BY SEROTYPE, 2018-2030 (USD MILLION)
  • TABLE 56 JAPAN: MENINGOCOCCAL VACCINES MARKET, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 57 CHINA: MENINGOCOCCAL VACCINES MARKET, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 58 CHINA: MENINGOCOCCAL VACCINES MARKET, BY SEROTYPE, 2018-2030 (USD MILLION)
  • TABLE 59 CHINA: MENINGOCOCCAL VACCINES MARKET, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 60 INDIA: MENINGOCOCCAL VACCINES MARKET, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 61 INDIA: MENINGOCOCCAL VACCINES MARKET, BY SEROTYPE, 2018-2030 (USD MILLION)
  • TABLE 62 INDIA: MENINGOCOCCAL VACCINES MARKET, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 63 AUSTRALIA: MENINGOCOCCAL VACCINES MARKET, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 64 AUSTRALIA: MENINGOCOCCAL VACCINES MARKET, BY SEROTYPE, 2018-2030 (USD MILLION)
  • TABLE 65 AUSTRALIA: MENINGOCOCCAL VACCINES MARKET, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 66 SOUTH KOREA: MENINGOCOCCAL VACCINES MARKET, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 67 SOUTH KOREA: MENINGOCOCCAL VACCINES MARKET, BY SEROTYPE, 2018-2030 (USD MILLION)
  • TABLE 68 SOUTH KOREA: MENINGOCOCCAL VACCINES MARKET, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 69 REST OF ASIA-PACIFIC: MENINGOCOCCAL VACCINES MARKET, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 70 REST OF ASIA-PACIFIC: MENINGOCOCCAL VACCINES MARKET, BY SEROTYPE, 2018-2030 (USD MILLION)
  • TABLE 71 REST OF ASIA-PACIFIC: MENINGOCOCCAL VACCINES MARKET, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 72 REST OF THE WORLD: MENINGOCOCCAL VACCINES MARKET, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 73 REST OF THE WORLD: MENINGOCOCCAL VACCINES MARKET, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 74 REST OF THE WORLD: MENINGOCOCCAL VACCINES MARKET, BY SEROTYPE, 2018-2030 (USD MILLION)
  • TABLE 75 REST OF THE WORLD: MENINGOCOCCAL VACCINES MARKET, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 76 MIDDLE EAST: MENINGOCOCCAL VACCINES MARKET, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 77 MIDDLE EAST: MENINGOCOCCAL VACCINES MARKET, BY SEROTYPE, 2018-2030 (USD MILLION)
  • TABLE 78 MIDDLE EAST: MENINGOCOCCAL VACCINES MARKET, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 79 AFRICA: MENINGOCOCCAL VACCINES MARKET, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 80 AFRICA: MENINGOCOCCAL VACCINES MARKET, BY SEROTYPE, 2018-2030 (USD MILLION)
  • TABLE 81 AFRICA: MENINGOCOCCAL VACCINES MARKET, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 82 LATIN AMERICA: MENINGOCOCCAL VACCINES MARKET, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 83 LATIN AMERICA: MENINGOCOCCAL VACCINES MARKET, BY SEROTYPE, 2018-2030 (USD MILLION)
  • TABLE 84 LATIN AMERICA: MENINGOCOCCAL VACCINES MARKET, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 85 MAJOR PLAYERS IN THE GLOBAL MENINGOCOCCAL VACCINES MARKET
  • TABLE 86 MOST ACTIVE PLAYER IN THE GLOBAL MENINGOCOCCAL VACCINES MARKET
  • TABLE 87 PRODUCT LAUNCH/ PRODUCT APPROVAL
  • TABLE 88 PARTERSHIP/AGREEMENT
  • TABLE 89 PFIZER INC: PRODUCTS/SERVICES OFFERED
  • TABLE 90 PFIZER INC.: KEY DEVELOPMENTS
  • TABLE 91 NOVARTIS AG: PRODUCTS/SERVICES OFFERED
  • TABLE 92 SANOFI S.A.: PRODUCTS/SERVICES OFFERED
  • TABLE 93 SANOFI S.A.: KEY DEVELOPMENTS
  • TABLE 94 SERUM INSTITUTE OF INDIA PVT. LTD.: PRODUCTS/SERVICES OFFERED
  • TABLE 95 GLAXOSMITHKLINE PLC.: PRODUCTS/SERVICES OFFERED
  • TABLE 96 MERCK & CO., INC.: PRODUCTS/SERVICES OFFERED
  • TABLE 97 MERCK & CO., INC.: KEY DEVELOPMENTS
  • TABLE 98 INCEPTA PHARMACEUTICALS LTD.: PRODUCTS/SERVICES OFFERED
  • TABLE 99 BIO-MED: PRODUCTS/SERVICES OFFERED
  • TABLE 100 WALVAX BIOTECHNOLOGY CO., LTD.: PRODUCTS/SERVICES OFFERED
  • TABLE 101 BIO-MANGUINHOS.: PRODUCTS/SERVICES OFFERED
  • TABLE 102 BIO-MANGUINHOS.: KEY DEVELOPMENTS  

LIST OF FIGURES

  • FIGURE 1 MARKET SYNOPSIS
  • FIGURE 2 GLOBAL MENINGOCOCCAL VACCINES MARKET
  • FIGURE 3 BOTTOM-UP AND TOP-DOWN APPROACHES
  • FIGURE 4 MARKET DYNAMICS: ANALYSIS OF THE GLOBAL MENINGOCOCCAL VACCINE MARKET
  • FIGURE 5 DRIVER IMPACT ANALYSIS
  • FIGURE 6 RESTRAINT IMPACT ANALYSIS
  • FIGURE 7 VALUE CHAIN ANALYSIS: GLOBAL MENINGOCOCCAL VACCINE MARKET
  • FIGURE 9 GLOBAL MENINGOCOCCAL VACCINES MARKET, BY VACCINE TYPE, 2021 & 2030 (USD MILLION)
  • FIGURE 10 GLOBAL: MENINGOCOCCAL VACCINES MARKET, BY SEROYYPE, 2021 & 2030 (USD MILLION)
  • FIGURE 11 GLOBAL: MENINGOCOCCAL VACCINES MARKET, BY END USER, 2021 & 2030 (USD MILLION)
  • FIGURE 12 GLOBAL: MENINGOCOCCAL VACCINES MARKET, BY REGION 2020 & 2030 (USD MILLION)
  • FIGURE 13 GLOBAL: MENINGOCOCCAL VACCINES MARKET SHARE (%), BY REGION, 2021
  • FIGURE 14 NORTH AMERICA: MENINGOCOCCAL VACCINES MARKET SHARE (%), BY COUNTRY 2021
  • FIGURE 15 EUROPE: MENINGOCOCCAL VACCINES MARKET SHARE (%), BY COUNTRY 2021
  • FIGURE 16 ASIA-PACIFIC: MENINGOCOCCAL VACCINES MARKET SHARE (%), BY COUNTRY 2021
  • FIGURE 17 REST OF THE WORLD: MENINGOCOCCAL VACCINES MARKET SHARE (%), BY REGION 2021
  • FIGURE 18 BENCHMARKING OF MAJOR COMPETITORS
  • FIGURE 19 MAJOR STRATEGY ADOPTED BY KEY PLAYERS IN THE GLOBAL MENINGOCOCCAL VACCINES MARKET
  • FIGURE 20 GLOBAL MENINGOCOCCAL VACCINES MARKET: COMPETITIVE LANDSCAPE
  • FIGURE 21 SALES 2021
  • FIGURE 22 R&D EXPENDITURE, 2021
  • FIGURE 23 PFIZER INC: FINANCIAL OVERVIEW SNAPSHOT
  • FIGURE 24 PFIZER INC: SWOT ANALYSIS
  • FIGURE 25 NOVARTIS AG: FINANCIAL OVERVIEW SNAPSHOT
  • FIGURE 26 NOVARTIS AG: SWOT ANALYSIS
  • FIGURE 27 SANOFI S.A.: FINANCIAL OVERVIEW SNAPSHOT
  • FIGURE 28 SANOFI S.A.: SWOT ANALYSIS
  • FIGURE 29 SERUM INSTITUTE OF INDIA PVT. LTD.: SWOT ANALYSIS
  • FIGURE 30 GLAXOSMITHKLINE PLC.: FINANCIAL OVERVIEW SNAPSHOT
  • FIGURE 31 GLAXOSMITHKLINE PLC.: SWOT ANALYSIS
  • FIGURE 32 MERCK & CO., INC.: FINANCIAL OVERVIEW SNAPSHOT
目次
Product Code: MRFR/HC/7150-CR

Market Overview

Meningococcal Vaccines Market size is anticipated to register a healthy CAGR of 7.29% during the review period to reach USD 5.91 billion by the end of 2030. The key factors that drive the worldwide meningococcal antibodies market are the Rising mindfulness and flood in movement immunizations and the expansion in Research and development for antibody innovation. Expanding Consideration in Public Vaccination Projects is supposed to help the development of the meningococcal antibodies market. In any case, the rigid administrative rules and item reviews are expected to hamper market development.

The rising mindfulness about meningococcal antibodies and expanding antimicrobial of a few Neisseria meningitides clonal buildings is prompting a flood in vaccination programs across the globe. For example, a few Neisseria meningitides clonal buildings, especially CC4821 and CC11, keep on showing protection from anti-microbials. Furthermore, expanding episodes of meningococcal infections, likewise, drive the market. Besides, a rising number of voyagers and the incorporation of meningococcal immunization as an obligatory prerequisite for a couple of nations are likewise driving the market.

Market Segmentation

The market segmentation of meningococcal immunizations market is as follows

By Vaccine Type

  • Conjugate
  • Subcapsular
  • Polysaccharide

By Serotype

  • MenACWY
  • MenB/BC
  • MenC
  • MenAC
  • MenA

By End-user

  • Hospitals
  • Research & Academic Institutes
  • Others

Regional Analysis

North America ruled the worldwide meningococcal immunizations market in 2021. This is because of the presence of central members, a deeply grounded medical services foundation, ideal government drives for immunization improvement and conveyance, and an expansion in the quantity of Research and development associations. Moreover, adolescents, teens, and youthful grown-ups represent 21% of all meningococcal sickness cases in the US and are probably going to emphatically affect the meningococcal immunization market.

The meningococcal antibody market in Europe is being driven by non-benefit associations that give funding to explore projects, medical services proficient preparation, patient data and backing, and request driven by a critical expansion in routine vaccination.

As indicated by the European Place for Illness Counteraction and Control, obtrusive meningococcal sickness (IMD) is the main source of meningitis and septicemia, with an expected 200,000 cases happening every year. The sickness frequently advances quickly with a 8-15% case-casualty proportion. Certain European nations that are planning for a meningococcal immunization program are supporting the meningococcal immunization market.

The Asia-Pacific locale is supposed to show the most elevated CAGR from 2021 to 2030. This is because of the expanded transmission of meningococcal microbes which has brought about a critical expansion in the quantity of clinical projects for the viable improvement of meningococcal immunizations because of capricious events across various age gatherings and nations in the district. This has reinforced the Asia-Pacific meningococcal immunizations market.

Major Players

The prominent players operating in the global meningococcal vaccines market include Pfizer Inc (US), Novartis AG (Switzerland), Incepta Pharmaceuticals Ltd (Bangladesh), BIO-MED (US), Walvax Biotechnology Co., Sanofi S.A.(France), and Serum Institute of India Pvt. Ltd (India), GlaxoSmithKline plc (UK), Merck & Co., Inc (US), Ltd (China), Bio-Manguinhos (Brazil).

COVID 19 Impacts

We are continuously tracking the impact of the COVID-19 pandemic on various industries and verticals within all domains. Our research reports include the same and help you understand the drop and rise, owing to the impact of COVID-19 on the industries. Also, we help you to identify the gap between the demand and supply of your interested market. Moreover, the report helps you with the analysis, amended government regulations, and many other useful insights.

TABLE OF CONTENTS

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY

2 MARKET INTRODUCTION

  • 2.1 DEFINITION
  • 2.2 SCOPE OF THE STUDY
  • 2.3 RESEARCH OBJECTIVE
  • 2.4 MARKET STRUCTURE
  • 2.5 ASSUMPTIONS & LIMITATIONS

3 RESEARCH METHODOLOGY

  • 3.1 DATA MINING
  • 3.2 SECONDARY RESEARCH
  • 3.3 PRIMARY RESEARCH
  • 3.4 BREAKDOWN OF PRIMARY RESPONDENTS
  • 3.5 FORECASTING TECHNIQUES
  • 3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION
    • 3.6.1 BOTTOM-UP APPROACH
    • 3.6.2 TOP-DOWN APPROACH
  • 3.7 DATA TRIANGULATION
  • 3.8 VALIDATION

4 MARKET DYNAMICS

  • 4.1 OVERVIEW
  • 4.2 DRIVERS
    • 4.2.1 INCREASING AWARENESS AND SURGE IN TRAVEL VACCINE
    • 4.2.2 INCREASE IN R&D FOR VACCINE TECHNOLOGY
  • 4.3 RESTRAINTS
    • 4.3.1 STRINGENT REGULATORY GUIDELINES AND PRODUCT RECALLS
  • 4.4 OPPORTUNITIES
    • 4.4.1 INCREASING INCLUSION IN NATIONAL IMMUNIZATION PROGRAMS

5 MARKET FACTOR ANALYSIS

  • 5.1 VALUE CHAIN ANALYSIS
    • 5.1.1 R&D
    • 5.1.2 MANUFACTURING
    • 5.1.3 DISTRIBUTION & SALES
    • 5.1.4 POST-SALES MONITORING
  • 5.2 PORTER'S FIVE FORCES MODEL
    • 5.2.1 THREAT OF NEW ENTRANTS
    • 5.2.2 BARGAINING POWER OF SUPPLIERS
    • 5.2.3 BARGAINING POWER OF BUYERS
    • 5.2.4 THREAT OF SUBSTITUTES
    • 5.2.5 INTENSITY OF RIVALRY
  • 5.3 IMPACT OF COVID-19 ON THE GLOBAL MENINGOCOCCAL VACCINES MARKET
    • 5.3.1 OVERVIEW
    • 5.3.2 IMPACT ON SUPPLY CHAIN
    • 5.3.3 IMPACT ON PRODUCTION OF MENINGOCOCCAL VACCINE
    • 5.3.4 IMPACT ON KEY PLAYERS

6 GLOBAL MENINGOCOCCAL VACCINES MARKET, BY VACCINE TYPE

  • 6.1 OVERVIEW
  • 6.2 CONJUGATE
  • 6.3 SUBCAPSULAR
  • 6.4 POLYSACCHARIDE

7 GLOBAL MENINGOCOCCAL VACCINES MARKET, BY SEROTYPE

  • 7.1 OVERVIEW
  • 7.2 MENACWY
  • 7.3 MENB/BC
  • 7.4 MENC
  • 7.5 MENAC
  • 7.6 MENA

8 GLOBAL MENINGOCOCCAL VACCINES MARKET, BY END USER

  • 8.1 OVERVIEW
  • 8.2 HOSPITALS
  • 8.3 RESEARCH & ACADEMIC INSTITUTES
  • 8.4 OTHERS

9 GLOBAL MENINGOCOCCAL VACCINES MARKET, BY REGION

  • 9.1 OVERVIEW
  • 9.2 NORTH AMERICA
    • 9.2.1 US
    • 9.2.2 CANADA
  • 9.3 EUROPE
    • 9.3.1 GERMANY
    • 9.3.2 FRANCE
    • 9.3.3 UK
    • 9.3.4 ITALY
    • 9.3.5 SPAIN
    • 9.3.6 REST OF EUROPE
  • 9.4 ASIA-PACIFIC
    • 9.4.1 JAPAN
    • 9.4.2 CHINA
    • 9.4.3 INDIA
    • 9.4.4 AUSTRALIA
    • 9.4.5 SOUTH KOREA
    • 9.4.6 REST OF ASIA-PACIFIC
  • 9.5 REST OF THE WORLD
    • 9.5.1 MIDDLE EAST
    • 9.5.2 AFRICA
    • 9.5.3 LATIN AMERICA

10 COMPETITIVE LANDSCAPE

  • 10.1 OVERVIEW
  • 10.2 COMPETITIVE BENCHMARKING
  • 10.3 MAJOR GROWTH STRATEGY IN THE GLOBAL MENINGOCOCCAL VACCINES MARKET
  • 10.4 THE LEADING PLAYER IN TERMS OF THE NUMBER OF DEVELOPMENTS IN THE GLOBAL MENINGOCOCCAL VACCINES MARKET
  • 10.5 KEY DEVELOPMENT ANALYSIS
  • 10.6 KEY DEVELOPMENTS & GROWTH STRATEGIES
    • 10.6.1 PRODUCT LAUNCH/ PRODUCT APPROVAL
    • 10.6.2 PARTERSHIP/AGREEMENT
  • 10.7 FINANCIAL MATRIX
    • 10.7.1 SALES (USD MILLION), 2021
    • 10.7.2 R&D EXPENDITURE (USD MILLION), 2021

11 COMPANY PROFILES

  • 11.1 PFIZER INC.
    • 11.1.1 COMPANY OVERVIEW
    • 11.1.2 FINANCIAL OVERVIEW
    • 11.1.3 PRODUCTS/SERVICES OFFERED
    • 11.1.4 KEY DEVELOPMENTS
    • 11.1.5 SWOT ANALYSIS
    • 11.1.6 KEY STRATEGIES
  • 11.2 NOVARTIS AG
    • 11.2.1 COMPANY OVERVIEWS
    • 11.2.2 FINANCIAL OVERVIEW
    • 11.2.3 PRODUCTS/SERVICES OFFERED
    • 11.2.4 KEY DEVELOPMENTS
    • 11.2.5 SWOT ANALYSIS
    • 11.2.6 KEY STRATEGIES
  • 11.3 SANOFI S.A.
    • 11.3.1 COMPANY OVERVIEW
    • 11.3.2 FINANCIAL OVERVIEW
    • 11.3.3 PRODUCTS/SERVICES OFFERED
    • 11.3.4 KEY DEVELOPMENTS
    • 11.3.5 SWOT ANALYSIS
    • 11.3.6 KEY STRATEGIES
  • 11.4 SERUM INSTITUTE OF INDIA PVT. LTD.
    • 11.4.1 COMPANY OVERVIEW
    • 11.4.2 FINANCIAL OVERVIEW
    • 11.4.3 PRODUCTS/SERVICES OFFERED
    • 11.4.4 KEY DEVELOPMENTS
    • 11.4.5 SWOT ANALYSIS
    • 11.4.6 KEY STRATEGIES
  • 11.5 GLAXOSMITHKLINE PLC.
    • 11.5.1 COMPANY OVERVIEW
    • 11.5.2 FINANCIAL OVERVIEW
    • 11.5.3 PRODUCTS/SERVICES OFFERED
    • 11.5.4 KEY DEVELOPMENTS
    • 11.5.5 SWOT ANALYSIS
    • 11.5.6 KEY STRATEGIES
  • 11.6 MERCK & CO., INC.
    • 11.6.1 COMPANY OVERVIEW
    • 11.6.2 FINANCIAL OVERVIEW
    • 11.6.3 PRODUCTS OFFERED
    • 11.6.4 KEY DEVELOPMENTS
    • 11.6.5 KEY STRATEGIES
  • 11.7 INCEPTA PHARMACEUTICALS LTD.
    • 11.7.1 COMPANY OVERVIEW
    • 11.7.2 FINANCIAL OVERVIEW
    • 11.7.3 PRODUCTS/SERVICES OFFERED
    • 11.7.4 KEY DEVELOPMENTS
    • 11.7.5 KEY STRATEGIES
  • 11.8 BIO-MED
    • 11.8.1 COMPANY OVERVIEW
    • 11.8.2 FINANCIAL OVERVIEW
    • 11.8.3 PRODUCTS OFFERED
    • 11.8.4 KEY DEVELOPMENTS
    • 11.8.5 KEY STRATEGIES
  • 11.9 WALVAX BIOTECHNOLOGY CO., LTD.
    • 11.9.1 COMPANY OVERVIEW
    • 11.9.2 FINANCIAL OVERVIEW
    • 11.9.3 PRODUCTS/SERVICES OFFERED
    • 11.9.4 KEY DEVELOPMENTS
    • 11.9.5 KEY STRATEGIES
  • 11.10 BIO-MANGUINHOS
    • 11.10.1 COMPANY OVERVIEW
    • 11.10.2 FINANCIAL OVERVIEW
    • 11.10.3 PRODUCTS/SERVICES OFFERED
    • 11.10.4 KEY DEVELOPMENTS
    • 11.10.5 KEY STRATEGIES

12 APPENDIX

  • 12.1 REFERENCES
  • 12.2 RELATED REPORTS